 |
Indication & Dosage |
| |
| |
| Oral |
| TREATMENT OF SCHIZOPHRENIA |
| Adult:
Initially, 2 mg daily adjusted according to response by increments of 2-4 mg at intervals of not <1 wk. |
| Max Dosage: 20 mg/day. |
| |
| Oral |
| TREATMENT OF SCHIZOPHRENIA |
| Child:
12-18 yr: Initial dose: 1 mg daily |
| Max Dosage: 20 mg as a single daily dose. |
| |
| Oral |
| MANAGEMENT OF MONOSYMPTOMATIC HYPOCHONDRIA |
| Adult:
Initially, 4 mg daily adjusted according to response by increments of 2-4 mg at intervals of not <1 wk. Max dose: 16 mg/day.
Elderly: Half the usual initial dose. |
| |
| Oral |
| PARANOID STATES |
| Adult:
Initially, 4 mg daily adjusted according to response by increments of 2-4 mg at intervals of not <1 wk. Max dose: 16 mg/day.
Elderly: Half the usual initial dose. |
| Max Dosage: 16 mg daily. |
| |
| Oral |
| MANAGEMENT OF TOURETTE'S SYNDROME |
| Adult:
Initially, 1-2 mg or 200 mcg/kg daily. Max dose: 10 mg/day |
| |
| Oral |
| MANAGEMENT OF TOURETTE'S SYNDROME |
| Child:
>12 yr: initial dose: 50 mcg/kg. |
| Max Dosage: 10 mg daily. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
Parkinson's syndrome; epilepsy, pregnancy, lactation; hepatic or renal impairment; monitor ECG before and during treatment; review the need for continuing treatment if repolarisation changes occur. Monitor cardiac function in patients taking >16 mg daily. Electrolytes disturbances such as hypomagnesaemia or hypokalaemia may increase risk of cardiotoxicity. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Extrapyramidal reactions, insomnia, drowsiness, dizziness. ECG changes, dry mouth, constipation, urinary difficulty and blurred vision. |
| |
|
| Adverse Drug Reactions |
Neuroleptic malignant syndrome. |
| |
|
| Interactions |
Potentiates other CNS depressants eg, alcohol and benzodiazepines. Increased risk of arrhythmias due to prolonged QT interval with TCAs, terfenadine, astemizole, antimalarial and cisapride. Concurrent use with inhibitors of CYP3A4 or CYP2D6 may lead to increased plasma concentrations leading to cardiac arrhythmias. Imatinib may also raise the plasma concentrations of pimozide. Avoid use with drugs that cause electrolyte disturbances eg, diuretics. Propranolol and cimetidine decrease hepatic metabolism and increase efficacy and toxicity. Concurrent use with SSRIs may increase risk of extrapyramidal adverse effects and potentially fatal torsades de pointes arrhythmias. Concurrent use with grapefruit juice may increase the blood concentrations of pimozide. |
| |
|
|
|
